girentuximab

girentuximab

A chimeric IgG1 monoclonal antibody that targets carbonic anhydrase IX. Phase-1 and -2 studies of girentuximab plus low-dose IFN-alpha in patients with progressive metastatic renal cell carcinoma indicated that the combination therapy was safe, well tolerated and demonstrated clinical benefit in the patient population.
References in periodicals archive ?
WILEX's manufacturing partner Avid Bioservices Inc, a unit of Peregrine Pharmaceuticals (NASDAQ:PPHM), has completed the production run of the third consecutive consistency lot for process validation of the naked antibody Girentuximab.